Baumann BC, et al. - Whether stereotactic body radiotherapy (SBRT) can achieve excellent local control (LC) with satisfactory toxicity in treating hepatocellular carcinomas (HCC) lesions, even in advanced cirrhosis, was investigated in this study with 37 nonmetastatic HCC patients who received SBRT to 43 lesions between October 2012 and April 2016. Median dose was 50 Gy/5 fractions. The first 3 fractions were followed by a planned 1-month break for all Child-Pugh (CP) ≥B patients in order to evaluate hepatic toxicity. Findings demonstrated good tolerability of SBRT for HCC, even in patients with advanced cirrhosis and prior liver-directed treatment. Even the larger lesions that could not be controlled with radiofrequency ablation were very well controlled locally with SBRT. LC provided by SBRT compared favorably to other liver-directed therapies.